Detalles de la búsqueda
1.
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments.
Invest New Drugs
; 41(2): 356-364, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37036580
2.
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Cancer Sci
; 113(1): 221-228, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34704312
3.
Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Invest New Drugs
; 40(1): 106-114, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34495421
4.
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.
Invest New Drugs
; 40(2): 403-410, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34633575
5.
Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.
Invest New Drugs
; 40(2): 411-419, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716848
6.
Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.
Support Care Cancer
; 30(2): 1633-1641, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34550461
7.
Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer.
Int J Clin Oncol
; 27(6): 1025-1033, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305192
8.
Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy.
Cancer Sci
; 112(1): 359-368, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098119
9.
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Invest New Drugs
; 39(2): 571-577, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32955628
10.
Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.
Invest New Drugs
; 39(6): 1716-1723, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34046801
11.
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
Invest New Drugs
; 39(6): 1732-1741, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34259953
12.
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
BMC Cancer
; 21(1): 1247, 2021 Nov 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-34798865
13.
Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors.
Jpn J Clin Oncol
; 51(12): 1736-1743, 2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34642738
14.
A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914.
Jpn J Clin Oncol
; 51(5): 836-841, 2021 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33728436
15.
Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer.
Support Care Cancer
; 29(7): 3961-3970, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33392773
16.
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Int J Clin Oncol
; 26(4): 659-669, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33415571
17.
Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
Invest New Drugs
; 38(1): 194-201, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31183631
18.
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.
Invest New Drugs
; 38(5): 1612-1617, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32128667
19.
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
Jpn J Clin Oncol
; 50(5): 617-622, 2020 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32211792
20.
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein.
Invest New Drugs
; 37(1): 184-187, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29971546